Nicholas Investment Partners LP Acquires Shares of 50,958 Janux Therapeutics, Inc. (NASDAQ:JANX)

Nicholas Investment Partners LP purchased a new position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 50,958 shares of the company's stock, valued at approximately $2,728,000. Nicholas Investment Partners LP owned about 0.10% of Janux Therapeutics at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Russell Investments Group Ltd. lifted its stake in shares of Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after purchasing an additional 442 shares in the last quarter. Avanza Fonder AB purchased a new stake in shares of Janux Therapeutics during the 4th quarter valued at about $139,000. Meeder Asset Management Inc. purchased a new stake in shares of Janux Therapeutics during the 4th quarter valued at about $159,000. Tower Research Capital LLC TRC raised its holdings in shares of Janux Therapeutics by 878.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company's stock valued at $205,000 after buying an additional 3,436 shares during the period. Finally, Brevan Howard Capital Management LP purchased a new stake in Janux Therapeutics during the 4th quarter worth approximately $221,000. 75.39% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $32.15, for a total transaction of $107,188.10. Following the sale, the insider now owns 82,139 shares in the company, valued at approximately $2,640,768.85. This represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. bought 110,206 shares of the company's stock in a transaction that occurred on Friday, March 7th. The shares were bought at an average price of $31.02 per share, for a total transaction of $3,418,590.12. Following the acquisition, the director now directly owns 10,141,287 shares of the company's stock, valued at $314,582,722.74. This represents a 1.10% increase in their position. The disclosure for this purchase can be found here. Insiders sold 10,001 shares of company stock valued at $313,964 over the last three months. Company insiders own 8.10% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on JANX shares. Wedbush restated an "outperform" rating and set a $76.00 price objective (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Scotiabank reduced their price target on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research report on Friday, February 28th. Finally, HC Wainwright restated a "buy" rating and issued a $70.00 price objective on shares of Janux Therapeutics in a report on Monday, March 3rd. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $95.25.

Janux Therapeutics Stock Performance

NASDAQ:JANX traded down $0.44 on Monday, reaching $23.84. The company's stock had a trading volume of 302,552 shares, compared to its average volume of 866,513. Janux Therapeutics, Inc. has a 1-year low of $22.48 and a 1-year high of $71.71. The firm has a market cap of $1.41 billion, a PE ratio of -20.38 and a beta of 3.24. The business's 50-day moving average price is $28.66 and its two-hundred day moving average price is $40.54.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, sell-side analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.